While substituting bivalirudin (Angiomax, The Medicines Company) for unfractionated heparin may be reasonably cost effective for patients at a high risk for bleeding after PCI, it is not cost effective for the majority of patients (90 percent or greater) at a low or moderate risk for bleeding, according to a study published in the July edition of Circulation: Cardiovascular Quality and Outcomes.
